{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T19:55:58Z","timestamp":1774122958321,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,21]]},"DOI":"10.7759\/cureus.105612","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T19:00:07Z","timestamp":1774119607000},"source":"Crossref","is-referenced-by-count":0,"title":["Impact of Dual-Tracer \u2076\u2078Ga-PSMA\/\u00b9\u2078F-FDG PET\/CT on the Characterization of Tumor Heterogeneity and Clinical Decision-Making in Metastatic Prostate Cancer: An Index Case From Ecuador"],"prefix":"10.7759","author":[{"given":"Sebastian","family":"Molina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana P","family":"Noboa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Cornejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref2","unstructured":"Global Cancer Observatory. Ecuador. (2024). Accessed: March 8, 2026: https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/218-ecuador-fact-sheet.pdf."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer - 2024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford P","year":"2024","unstructured":"Cornford P, van den Bergh RC, Briers E, et al.. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer - 2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024, 86:148-63. 10.1016\/j.eururo.2024.03.027","journal-title":"Eur Urol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.198119","article-title":"Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT","volume":"59","author":"Eiber M","year":"2018","unstructured":"Eiber M, Herrmann K, Calais J, et al.. Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT. J Nucl Med. 2018, 59:469-78. 10.2967\/jnumed.117.198119","journal-title":"J Nucl Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.12182\/20240960201","article-title":"Clinical value of dual tracer PET imaging with 68Ga-PSMA and 18F-FDG in patients with metastatic prostate cancer","volume":"55","author":"Dai H","year":"2024","unstructured":"Dai H, Huang S, Tian T, Hou N, Zeng H, Wei Q, Huang R. Clinical value of dual tracer PET imaging with 68Ga-PSMA and 18F-FDG in patients with metastatic prostate cancer. Sichuan Da Xue Xue Bao Yi Xue Ban. 2024, 55:1063-70. 10.12182\/20240960201","journal-title":"Sichuan Da Xue Xue Bao Yi Xue Ban"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.722277","article-title":"Incorporating PSMA-targeting theranostics into personalized prostate cancer treatment: a multidisciplinary perspective","volume":"11","author":"Ng TS","year":"2021","unstructured":"Ng TS, Gao X, Salari K, Zlatev DV, Heidari P, Kamran SC. Incorporating PSMA-targeting theranostics into personalized prostate cancer treatment: a multidisciplinary perspective. Front Oncol. 2021, 11:722277. 10.3389\/fonc.2021.722277","journal-title":"Front Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman MS","year":"2018","unstructured":"Hofman MS, Violet J, Hicks RJ, et al.. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018, 19:825-33. 10.1016\/S1470-2045(18)30198-0","journal-title":"Lancet Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2021.39.15_suppl.lba4","article-title":"Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION)","volume":"39","author":"Morris MJ","year":"2021","unstructured":"Morris MJ, De Bono JS, Chi KN, et al.. Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION). J Clin Oncol. 2021, 39:LBA4. 10.1200\/jco.2021.39.15_suppl.lba4","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"399","author":"Fizazi K","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J, et al.. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design. Lancet. 2022, 399:1695-707. 10.1016\/S0140-6736(22)00367-1","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith MR","year":"2022","unstructured":"Smith MR, Hussain M, Saad F, et al.. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022, 386:1132-42. 10.1056\/NEJMoa2119115","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis ID","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, et al.. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019, 381:121-31. 10.1056\/NEJMoa1903835","journal-title":"N Engl J Med"},{"key":"ref12","unstructured":"NCCN guidelines. prostate cancer. (2026). Accessed: March 17, 2026: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1459."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-010-0527-5","article-title":"Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer","volume":"28","author":"Reuter CW","year":"2010","unstructured":"Reuter CW, Morgan MA, Ivanyi P, Fenner M, Ganser A, Gr\u00fcnwald V. Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer. World J Urol. 2010, 28:391-8. 10.1007\/s00345-010-0527-5","journal-title":"World J Urol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23195","article-title":"A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel","volume":"112","author":"Ross RW","year":"2008","unstructured":"Ross RW, Beer TM, Jacobus S, et al.. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer. 2008, 112:521-6. 10.1002\/cncr.23195","journal-title":"Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.21873\/cdp.10060","article-title":"Efficacy of combination chemotherapy with docetaxel, estramustine and carboplatin in men with castration-resistant prostate cancer","volume":"1","author":"Hikita K","year":"2021","unstructured":"Hikita K, Honda M, Shimizu R, et al.. Efficacy of combination chemotherapy with docetaxel, estramustine and carboplatin in men with castration-resistant prostate cancer. Cancer Diagn Progn. 2021, 1:451-7. 10.21873\/cdp.10060","journal-title":"Cancer Diagn Progn"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.16_suppl.5054","article-title":"Final results of a pilot study of docetaxel and carboplatin for treatment of patients with mCRPC containing biallelic inactivation of genes in the homologous recombination DNA repair pathway","volume":"41","author":"Raychaudhuri R","year":"2023","unstructured":"Raychaudhuri R, DeJong M, Yu EY, et al.. Final results of a pilot study of docetaxel and carboplatin for treatment of patients with mCRPC containing biallelic inactivation of genes in the homologous recombination DNA repair pathway. J Clin Oncol. 2023, 41:5054. 10.1200\/jco.2023.41.16_suppl.5054","journal-title":"J Clin Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.01.043","article-title":"Clinical and genomic characterization of low-prostate-specific antigen, high-grade prostate cancer","volume":"74","author":"Mahal BA","year":"2018","unstructured":"Mahal BA, Yang DD, Wang NQ, et al.. Clinical and genomic characterization of low-prostate-specific antigen, high-grade prostate cancer. Eur Urol. 2018, 74:146-54. 10.1016\/j.eururo.2018.01.043","journal-title":"Eur Urol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2018.09.014","article-title":"Results of a prospective phase 2 pilot trial of 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment response and patterns of progression","volume":"17","author":"Emmett L","year":"2019","unstructured":"Emmett L, Crumbaker M, Ho B, et al.. Results of a prospective phase 2 pilot trial of 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment response and patterns of progression. Clin Genitourin Cancer. 2019, 17:15-22. 10.1016\/j.clgc.2018.09.014","journal-title":"Clin Genitourin Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3329\/bjnm.v28i1.79558","article-title":"18F PSMA-1007 and 18F FDG PET\/CT in an advanced prostate cancer patient - a case report","volume":"28","author":"Mutsuddy P","year":"2025","unstructured":"Mutsuddy P, Mandal T, Akhter P, et al.. 18F PSMA-1007 and 18F FDG PET\/CT in an advanced prostate cancer patient - a case report. Bangladesh J Nucl Med. 2025, 28:174-7. 10.3329\/bjnm.v28i1.79558","journal-title":"Bangladesh J Nucl Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2018.11.007","article-title":"Poor outcomes for patients with metastatic castration-resistant prostate cancer with low prostate-specific membrane antigen (PSMA) expression deemed ineligible for 177Lu-labelled PSMA radioligand therapy","volume":"2","author":"Thang SP","year":"2019","unstructured":"Thang SP, Violet J, Sandhu S, et al.. Poor outcomes for patients with metastatic castration-resistant prostate cancer with low prostate-specific membrane antigen (PSMA) expression deemed ineligible for 177Lu-labelled PSMA radioligand therapy. Eur Urol Oncol. 2019, 2:670-6. 10.1016\/j.euo.2018.11.007","journal-title":"Eur Urol Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/449566-impact-of-dual-tracer-ga-psmaf-fdg-petct-on-the-characterization-of-tumor-heterogeneity-and-clinical-decision-making-in-metastatic-prostate-cancer-an-index-case-from-ecuador","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T19:00:10Z","timestamp":1774119610000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/449566-impact-of-dual-tracer-ga-psmaf-fdg-petct-on-the-characterization-of-tumor-heterogeneity-and-clinical-decision-making-in-metastatic-prostate-cancer-an-index-case-from-ecuador"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,21]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.105612","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,21]]}}}